Michael Weiss
Chief Executive Officer at TG THERAPEUTICS, INC.
Net worth: 216 M $ as of 2024-05-30
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Lindsay Rosenwald | M | 68 |
Helocyte, Inc.
Helocyte, Inc. Miscellaneous Commercial ServicesCommercial Services Helocyte, Inc. engages in the development and commercialization of immunotherapies for the prevention and treatment of cytomegalovirus or CMV (cancer and infectious disease). It focuses on developing PepVax, a HLA-restricted single antigen peptide vaccine for controlling CMV in allogeneic hematopoietic stem cell transplant recipients and Triplex. The company was founded by Donald J. Diamond in 2015 and is headquartered in New York, NY.
Baergic Bio, Inc.
Baergic Bio, Inc. Pharmaceuticals: MajorHealth Technology Baergic Bio, Inc. develops therapeutic drugs for the treatment of central nervous system disorders. It offers oncology, rare diseases, and gene therapy. The company is headquartered in New York, NY.
Cellvation, Inc.
Cyprium Therapeutics, Inc.
Cyprium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Fortress Biotech, Inc., Cyprium Therapeutics, Inc. is an American New York-based company focused on developing novel therapies for the treatment of Menkes disease and related copper metabolism disorders. The company was granted FDA breakthrough therapy, fast track, and rare pediatric disease designations, as well as FDA orphan drug designation for both Cutx-101 and AAV-ATP7A. The European Medicines Agency also granted orphan drug designation to Cyprium. In March 2017, Cyprium entered into a cooperative research and development agreement with the Eunice Kennedy Shriver National Institute of Child Health and Human Development to advance the clinical development of Cutx-101 for the treatment of Menkes disease. In 2023, Cyprium completed the transfer of its proprietary rights and assigned its FDA documents pertaining to Cutx-101 to Sentynl Therapeutics, Inc. Cyprium and NICHD also previously entered into a worldwide, exclusive license agreement to develop and commercialize AAV-ATP7A gene therapy, which is currently in pre-clinical development. The company was founded in 2017 by Michael Sean Weiss, Lindsay Allan Rosenwald, and Lung S. Yam, who has been the CEO since then. | 28 years |
Neil Herskowitz | M | 67 | 20 years | |
James Oliviero | M | 48 |
ACCESS Oncology, Inc.
ACCESS Oncology, Inc. Pharmaceuticals: OtherHealth Technology Part of Akebia Therapeutics, Inc., ACCESS Oncology, Inc. is a company that develops pharmaceutical drugs. The company is based in New York, NY. The company was founded by Michael Sean Weiss. ACCESS Oncology was acquired by Keryx Biopharmaceuticals, Inc., part of Akebia Therapeutics, Inc. from December 13, 2018 on February 06, 2004 for $36.44 million. | 25 years |
Frank Taffy | M | - |
Cellvation, Inc.
Helocyte, Inc.
Helocyte, Inc. Miscellaneous Commercial ServicesCommercial Services Helocyte, Inc. engages in the development and commercialization of immunotherapies for the prevention and treatment of cytomegalovirus or CMV (cancer and infectious disease). It focuses on developing PepVax, a HLA-restricted single antigen peptide vaccine for controlling CMV in allogeneic hematopoietic stem cell transplant recipients and Triplex. The company was founded by Donald J. Diamond in 2015 and is headquartered in New York, NY. | 9 years |
William Gray | M | 36 | 8 years | |
Adam Chill | M | 56 | 10 years | |
Daniel Hume | M | 57 | 9 years | |
Manuel Litchman | M | 70 | 7 years | |
Xiao Qin Lu | M | 49 | 8 years | |
Jay Kranzler | M | 66 |
Baergic Bio, Inc.
Baergic Bio, Inc. Pharmaceuticals: MajorHealth Technology Baergic Bio, Inc. develops therapeutic drugs for the treatment of central nervous system disorders. It offers oncology, rare diseases, and gene therapy. The company is headquartered in New York, NY. | 7 years |
Sean Power | M | 42 | 18 years | |
Brian Achenbach | M | 59 | 7 years | |
George Avgerinos | M | 71 | 11 years | |
Lung S. Yam | M | - |
Cyprium Therapeutics, Inc.
Cyprium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Fortress Biotech, Inc., Cyprium Therapeutics, Inc. is an American New York-based company focused on developing novel therapies for the treatment of Menkes disease and related copper metabolism disorders. The company was granted FDA breakthrough therapy, fast track, and rare pediatric disease designations, as well as FDA orphan drug designation for both Cutx-101 and AAV-ATP7A. The European Medicines Agency also granted orphan drug designation to Cyprium. In March 2017, Cyprium entered into a cooperative research and development agreement with the Eunice Kennedy Shriver National Institute of Child Health and Human Development to advance the clinical development of Cutx-101 for the treatment of Menkes disease. In 2023, Cyprium completed the transfer of its proprietary rights and assigned its FDA documents pertaining to Cutx-101 to Sentynl Therapeutics, Inc. Cyprium and NICHD also previously entered into a worldwide, exclusive license agreement to develop and commercialize AAV-ATP7A gene therapy, which is currently in pre-clinical development. The company was founded in 2017 by Michael Sean Weiss, Lindsay Allan Rosenwald, and Lung S. Yam, who has been the CEO since then. | 7 years |
Kenneth Hoberman | M | 59 | 19 years | |
Malcolm Hoenlein | M | 80 | 17 years | |
Michael Anthony Mullen | M | 56 | 7 years | |
Laurence Charney | M | 76 | 12 years | |
Christian Béchon | M | 63 | 6 years | |
Greg Furrow | M | - | 5 years | |
Samuel Berry | M | - | 8 years | |
David Jin | M | 34 | - | |
Sagar Lonial | M | 57 | 4 years | |
Kevin Lorenz | M | 59 | 5 years | |
J. Lobell | M | 61 | 18 years | |
James Murphy | M | 67 | - | |
Michael Zelefsky | M | 63 | 7 years | |
Jaclyn Jaffe | F | - | - | |
Jimmie Harvey | M | 72 | 16 years | |
Barry Salzman | M | 62 | 8 years | |
Yann Echelard | M | 60 | 12 years | |
Dov Klein | M | 72 | 9 years | |
Jenna A. Bosco | F | - | 13 years | |
Bruce Dezube | M | - | 3 years | |
Jaclyn Jaffe | F | - | - | |
Adam Waldman | M | - | 6 years | |
Debra Manning | F | - | 5 years | |
Scott Reines | M | 77 | 8 years | |
Michael Ryan | M | - | 6 years | |
Nicole McCloskey | F | - | - | |
Peter Carney | M | 38 | 3 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Jose M. Aldeanueva | M | 55 | - | |
Michael Tarnok | M | 69 | 9 years | |
Robyn Hunter | F | 62 | 11 years | |
Robert Fagenson | M | 75 | 9 years | |
Michael G. McGuinness | M | 70 | 5 years | |
Goldie Goldwasser | M | 64 | 16 years | |
Beth Levine | F | 60 | 1 years | |
Joseph Vazzano | M | 40 | 5 years | |
David J. Horin | M | 56 | 2 years | |
Mark Klein | M | 60 | 3 years | |
Douglas A. Abel | M | 62 | 6 years | |
Harlan Weisman | M | 71 | 1 years | |
Mark Stier | M | 63 | 1 years | |
Jack Kaye | M | 80 | 10 years | |
David Shimko | M | 63 | 1 years | |
Kevin Cameron | M | 64 | 11 years | |
Scott Boilen | M | 57 | 8 years | |
Michelle Y. Carroll | F | - | - | |
Marshall Geller | M | 85 | 6 years | |
Paul J. Coviello | M | 70 | 2 years | |
Jeff Paley | M | 55 | 4 years | |
Jeffrey J. Gutovich | M | 67 | - | |
Michael T. Eustace | M | - | 1 years | |
Nishant Saxena | M | 48 | - | |
Sadik Kassim | M | - | 2 years | |
Knut Niss | M | - | - | |
Jaideep Gogtay | M | 58 | 3 years | |
Matthew Wein, | - | - | - | |
Michael Singer | M | 57 | 4 years | |
Alan B. Levin | M | 60 | 8 years | |
Jorge A. Ortega | M | 59 | 4 years | |
Malcolm Morville | M | 78 | - | |
Wyche Fowler | M | 83 | 10 years | |
Richard Steinhart | M | 66 | 8 years | |
Athanassios Michas | M | 79 | 2 years | |
I. Craig Henderson | M | 82 |
ACCESS Oncology, Inc.
ACCESS Oncology, Inc. Pharmaceuticals: OtherHealth Technology Part of Akebia Therapeutics, Inc., ACCESS Oncology, Inc. is a company that develops pharmaceutical drugs. The company is based in New York, NY. The company was founded by Michael Sean Weiss. ACCESS Oncology was acquired by Keryx Biopharmaceuticals, Inc., part of Akebia Therapeutics, Inc. from December 13, 2018 on February 06, 2004 for $36.44 million. | 7 years |
Nicholas J. Rossettos | M | - | - | |
Barry Rodgers | M | 84 | - | |
Michael Rogers | M | 64 | 2 years | |
Eli Salig | M | 74 | 3 years | |
Ronald Bentsur | M | 58 | 6 years | |
Morris Laster | M | 60 | 5 years | |
Mark J. Schoenebaum | M | 51 | 7 years | |
H. Laurence Shaw | M | - | - | |
Akhtar Samad | M | 64 | 4 years | |
Ronald Renaud | M | 55 | 1 years | |
Stephen B. Pudles | M | 63 | - | |
William James Kennedy | M | 79 | 9 years | |
Arthur Asher Kornbluth | M | 64 | 2 years | |
Eric Rose | M | 73 | - | |
Alexandra MacLean | M | 57 | 1 years | |
Alan G. Harris | M | 72 | 1 years | |
Enrique Poradosu | M | 58 | 13 years | |
BILL Kessler | M | 57 | 2 years | |
Hadas Reuveni | M | 56 | 3 years | |
Scott A. Holmes | M | 50 | 2 years | |
William Kane | M | 62 | - | |
Robert Sexton | M | - | 2 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 95 | 95.96% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Michael Weiss
- Personal Network